We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways. Advanced clinical trials with Rigosertib are aimed at the unmet medical needs of patients with MDS. There has not been an FDA-approved treatment for higher-risk MDS in over a decade. Both IV and oral rigosertib are protected by issued patents worldwide (earliest expiry 2026) and have been granted orphan drug designation for MDS in the US, Europe, and Japan. Very promising data from the Phase 2 combination trial of o